Microfluidic synthesis of PLGA/carbon quantum dot microspheres for vascular endothelial growth factor delivery

Omidi, Meisam; Hashemi, Mohadeseh

doi:10.1039/c9ra06279c

Cited by 17 publications

(8 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…dipalmitoylphosphatidylcholine (DPPC) nanoparticles which was loaded with VEGF; slow and sustained release over 28 days was reported resulting in promoted proliferation of human umbilical vein endothelial cells [69]. Similarly, Tayebi research team fabricated PLGA microspheres with average sized of 16-36 µm for controlled release of VEGF [70]. A recent effort reviewed the potential and applications of various micro-sized particles for controlled and sustained GF release [71].…”

Section: Growth Factorsmentioning

confidence: 99%

Prevascularized Micro-/Nano-Sized Spheroid/Bead Aggregates for Vascular Tissue Engineering

et al. 2021

View full text Add to dashboard Cite

Efficient strategies to promote microvascularization in vascular tissue engineering, a central priority in regenerative medicine, are still scarce; nano- and micro-sized aggregates and spheres or beads harboring primitive microvascular beds are promising methods in vascular tissue engineering. Capillaries are the smallest type and in numerous blood vessels, which are distributed densely in cardiovascular system. To mimic this microvascular network, specific cell components and proangiogenic factors are required. Herein, advanced biofabrication methods in microvascular engineering, including extrusion-based and droplet-based bioprinting, Kenzan, and biogripper approaches, are deliberated with emphasis on the newest works in prevascular nano- and micro-sized aggregates and microspheres/microbeads.

show abstract

Section: Growth Factorsmentioning

confidence: 99%

Prevascularized Micro-/Nano-Sized Spheroid/Bead Aggregates for Vascular Tissue Engineering

et al. 2021

View full text Add to dashboard Cite

show abstract

“…[ 101 ] Among these, poly(lactic‐co‐glycolic acid) (PLGA), is a well‐researched polymeric material approved by the FDA as a safety drug vehicle. [ 71 , 75 , 102 ] Biopolymers, such as proteins, gelatin, chitosan and alginate, are used to produce drug‐loaded microparticles using microfluidics to study cell responses, both in vitro and in vivo. [ 103 , 104 , 105 , 106 ] Other stimuli‐responsive microparticles produced using microfluidics include PEG, [ 107 ] polylactide, [ 108 ] graphene oxide, [ 109 ] polyurea, [ 110 ] polyester, [ 93 ] poly(N‐vinylcaprolactam), [ 89 ] and fatty alcohol ( Figure 3 b ), [ 91 ] tailored with properties for various biomedical and drug delivery applications.…”

Section: Drug Delivery Systems and Droplet‐based Technologymentioning

confidence: 99%

Droplet Microfluidics for Tumor Drug‐Related Studies and Programmable Artificial Cells

Dimitriou

Tornillo

et al. 2021

Global Challenges

View full text Add to dashboard Cite

(1 of 17)www.global-challenges.com robotics, have promoted the use of in vitro tumor models in high-throughput drug screenings. [2,3] High-throughput screens for anticancer drugs have been, for a long time, limited to 2D culture of tumor cells, grown as a monolayer on the bottom of a well of a microtiter plate. Compared to 2D cell cultures, 3D culture systems can more faithfully model cell-cell interactions, matrix deposition and tumor microenvironments, including more physiological flow conditions, oxygen and nutrient gradients. [4] Therefore, 3D cultures have recently begun to be incorporated into high-throughput drug screenings, with the aim of better predicting drug efficacy and improving the prioritization of candidate drugs for further in vivo testing in animals.Because of the relatively simple, reproducible, amenable to automation and scalable culture methods, single-cell type and mixed-cell tumor spheroids, known as multicellular tumor spheroids (MCTSs), are used as 3D models. [5] There exists a broad range of natural hydrogels that are compatible with microfluidics, and which provide cancer cells with mechanical cues and adhesion sites to proliferate and grow into MCTSs. [6] With the aid of microfluidics and development of more complex 3D tumor models, [7,8] and the large-scale production of tumor spheroids in hydrogels, the number of compounds that could progress to in vivo testing could be restricted, thus reducing the number of animals needed for preclinical studies.Tumor-targeted drug delivery using microparticles and liposomes is beneficial compared to conventional drug administration. This is because encapsulated drug dosages can be controlled, healthy tissues can remain unharmed during treatment and drug resistance of cancer cells may be reduced/ prevented. [9,10] Microparticles and liposomes can be tailored to specifically target tumor sites using molecular conjugates, while avoiding toxic effects. [9] This review discusses the application of droplet-based microfluidic technologies for the development of accurate in vitro tumor models and improved cancer treatment strategies. The first part of the review centers around the generation of MCTSs in natural hydrogels for a better recapitulation of the in vivo tumor microenvironment. The second section is focused on microparticle and liposomal production for tumor-targeted drug delivery. Emphases is given to microfluidic methodologies for the production of these systems, and the potential of compartmentalized artificial cells as anticancer drug screening platforms.

show abstract

“…Carbon nanoparticles (carbon dots, CDs) opened new opportunities in the field of nanomedicine due to their excitation wavelength-dependent photoluminescence emission, dispersibility in water, biocompatibility, and high cell membrane permeability . Surface functional groups, such as hydroxyl, amino, and carboxylic groups, are amenable for CD conjugation with drugs. − Furthermore, CDs exhibit high resistance to photobleaching. , Fluorescent CDs have been conjugated to antibodies and anticancer drugs − and mixed with VEGF . Covalent linking of CDs to VEGF while still preserving its angiogenic performance would enable noninvasive detection of this growth factor during angiogenesis in injured tissues; however, it has not been reported.…”

Section: Introductionmentioning

confidence: 99%

Carbon Dots Conjugated with Vascular Endothelial Growth Factor for Protein Tracking in Angiogenic Therapy

et al. 2020

View full text Add to dashboard Cite

One of the challenges of using growth factors for tissue regeneration is to monitor their biodistributions and delivery to injured tissues for minimally invasive detection. In the present study, tracking of human vascular endothelial growth factor (VEGF) was achieved by chemically linking it to photoluminescent carbon dots (CDs). Carbon dots were synthesized by the hydrothermal method and, subsequently, conjugated with VEGF using carbodiimide coupling. ELISA and western blot analysis revealed that VEGF-conjugated CDs preserve the binding affinity of VEGF to its antibodies. We also show that VEGF-conjugated CDs maintain the functionality of VEGF for tube formation and cell migration. The VEGF-conjugated CDs were also used for in vitro imaging of human umbilical vein endothelial cells. The results of this work suggest that cell-penetrating VEGF-conjugated CDs can be used for growth factor protein tracking in therapeutic and tissue engineering applications.

show abstract

Microfluidic synthesis of PLGA/carbon quantum dot microspheres for vascular endothelial growth factor delivery

Cited by 17 publications

References 37 publications

Prevascularized Micro-/Nano-Sized Spheroid/Bead Aggregates for Vascular Tissue Engineering

Prevascularized Micro-/Nano-Sized Spheroid/Bead Aggregates for Vascular Tissue Engineering

Droplet Microfluidics for Tumor Drug‐Related Studies and Programmable Artificial Cells

Carbon Dots Conjugated with Vascular Endothelial Growth Factor for Protein Tracking in Angiogenic Therapy

Contact Info

Product

Resources

About